Mésalazine : interactions médicamenteuses

Intervention: The concomitant use of mefenamic acid with other NSAIDs or salicylates is not recommended. (notice Acide méfénamique, Interactions médicamenteuses)

Antacids Because the dissolution of the coating of the granules in APRISO capsules depends on pH, avoid co-administration of APRISO capsules with antacids [see Dosage and Administration (2) ] . (notice Mésalazine, Interactions médicamenteuses)

If concomitant use of APRISO and azathioprine or 6-mercaptopurine cannot be avoided, monitor blood tests, including complete blood cell counts and platelet counts. (notice Mésalazine, Interactions médicamenteuses)

Antacids Because the dissolution of the coating of the granules in APRISO capsules depends on pH, avoid co-administration of APRISO capsules with antacids [see Dosage and Administration (2) ] . (notice Mésalazine, Interactions médicamenteuses)

Intervention: The concomitant use of Celecoxib with other NSAIDs or salicylates is not recommended. (notice Célécoxib, Interactions médicamenteuses)

Intervention: The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended. (notice Diclofénac, Interactions médicamenteuses)

Intervention: The concomitant use of diclofenac sodium/misoprostol with other NSAIDs or salicylates is not recommended. (notice Diclofénac et misoprostol, Interactions médicamenteuses)

Intervention: The concomitant use of fenoprofen with other NSAIDs or salicylates is not recommended. (notice Fénoprofène, Interactions médicamenteuses)

Intervention: The concomitant use of flurbiprofen with other NSAIDs or salicylates is not recommended. (notice Flurbiprofène, Interactions médicamenteuses)

The concomitant use of ibuprofen with other NSAIDs or salicylates is not recommended. (notice Hydrocodone et ibuprofène, Interactions médicamenteuses)

Intervention: The concomitant use of ibuprofen with other NSAIDs or salicylates is not recommended. (notice Ibuprofène, Interactions médicamenteuses)

Intervention: The concomitant use of ibuprofen and famotidine tablet with other NSAIDs or salicylates is not recommended. (notice Ibuprofène et famotidine, Interactions médicamenteuses)

Intervention: The concomitant use of indomethacin with other NSAIDs or salicylates, especially diflunisal, is not recommended. (notice Indométacine, Interactions médicamenteuses)

Intervention: The concomitant use of meloxicam with other NSAIDs or salicylates is not recommended. (notice Méloxicam, Interactions médicamenteuses)

If concomitant use of APRISO and azathioprine or 6-mercaptopurine cannot be avoided, monitor blood tests, including complete blood cell counts and platelet counts. (notice Mésalazine, Interactions médicamenteuses)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (notice Naproxène, Interactions médicamenteuses)

Intervention: The concomitant use of naproxen and esomeprazole magnesium delayed-release tablets with other NSAIDs or salicylates is not recommended. (notice Naproxène et ésoméprazole, Interactions médicamenteuses)

Antacids Because the dissolution of the coating of the granules in APRISO capsules depends on pH, avoid co-administration of APRISO capsules with antacids [see Dosage and Administration (2) ] . (notice Mésalazine, Interactions médicamenteuses)

Intervention: The concomitant use of oxaprozin with other NSAIDs or salicylates is not recommended. (notice Oxaprozine, Interactions médicamenteuses)

Intervention: The concomitant use of ibuprofen with other NSAIDs or salicylates is not recommended. (notice Paracétamol et ibuprofène, Interactions médicamenteuses)

Contraindications: ANTICHOLIUM ® should not be used in the presence of hypersensitivity to physostigmine salicylate, bronchial asthma, ulcers associated with tissue destruction (gangrene), coronary heart disease, constipation (mechanical obstipation), mechanical ischuria (urinary retention), hereditary form of muscle atrophy (myotonic dystrophy), closed traumatic… (notice Physostigmine, Contre-indications)

Intervention: The concomitant use of piroxicam with other NSAIDs or salicylates is not recommended. (notice Piroxicam, Interactions médicamenteuses)

In patients on probenecid the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (notice Probénécide, Mises en garde)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (notice Probénécide et colchicine, Mises en garde)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (notice Sumatriptan et naproxène, Interactions médicamenteuses)

Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with Adapalene Cream, 0.1%. (notice Adapalène, Interactions médicamenteuses)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (notice Mésalazine, Interactions médicamenteuses)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (notice Mésalazine, Interactions médicamenteuses)

Mesalamine-Induced Acute Intolerance Syndrome: Symptoms may be difficult to distinguish from an exacerbation of ulcerative colitis; monitor for worsening symptoms; discontinue treatment if acute intolerance syndrome is suspected. (notice Balsalazide, Mises en garde et précautions)

• Rare instances of acid-base alterations have occurred with high-dose salicylate therapy. (notice Brinzolamide, Interactions médicamenteuses)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (notice Bromocriptine, Interactions médicamenteuses)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (notice Mésalazine, Interactions médicamenteuses)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (notice Mésalazine, Interactions médicamenteuses)

NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. (notice Ciprofloxacine, Interactions médicamenteuses)

COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. (notice Désogestrel et éthinylestradiol, Interactions médicamenteuses)

The clearance of salicylates may be increased with concurrent use of corticosteroids. (notice Dexaméthasone, Interactions médicamenteuses)

Concomitant Use of Aspirin or Other Salicylates Carbonic anhydrase inhibitors, including KEVEYIS, can cause metabolic acidosis [see Warnings and Precautions (5.4) ] , which can increase the risk of salicylate toxicity. (notice Diclofénamide, Mises en garde et précautions)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (notice Mésalazine, Interactions médicamenteuses)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (notice Dorzolamide, Interactions médicamenteuses)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (notice Dorzolamide et timolol, Interactions médicamenteuses)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (notice Mésalazine, Interactions médicamenteuses)

CHCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid and temazepam. (notice Étonogestrel et éthinylestradiol, Interactions médicamenteuses)

Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy. (notice Fludrocortisone, Interactions médicamenteuses)

…sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antineoplastic agents usually in combination Bleomycin, carboplatin, cisplatin,… (notice Fosphénytoïne, Interactions médicamenteuses)

• Salicylates : Risk of salicylate toxicity ( 7.1 ) (notice Furosémide, Interactions médicamenteuses)

…Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. (notice Glibenclamide, Interactions médicamenteuses)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (notice Glimépiride, Interactions médicamenteuses)

…antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor… (notice Glipizide, Interactions médicamenteuses)

Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (notice Glipizide et metformine, Précautions)

Serum salicylate concentrations may be decreased when griseofulvin is given concomitantly with salicylates. (notice Griséofulvine, Interactions médicamenteuses)

• Large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect ( 7.4 ) (notice Hyaluronidase, Interactions médicamenteuses)

The clearance of salicylates may be increased with concurrent use of corticosteroids; this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. (notice Hydrocortisone, Interactions médicamenteuses)

Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. (notice Insuline asparte, Interactions médicamenteuses)

…May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. (notice Insuline dégludec, Interactions médicamenteuses)

…May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. (notice Insuline détémir, Interactions médicamenteuses)

…May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors. (notice Insuline glargine, Interactions médicamenteuses)

Clinically Significant Drug Interactions with LYUMJEV Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (notice Insuline lispro, Interactions médicamenteuses)

…agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically… (notice Insuline rapide (humaine), Interactions médicamenteuses)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (notice Mésalazine, Interactions médicamenteuses)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (notice Mésalazine, Interactions médicamenteuses)

Other Drugs Clinical effect Concomitant use of CHCs may decrease systemic exposure of acetaminophen, morphine, salicylic acid, and temazepam. (notice Lévonorgestrel et éthinylestradiol, Interactions médicamenteuses)

An initial increase in serum FT 4 is followed by return of FT 4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T 4 levels may decrease by as much as 30%. (notice Lévothyroxine, Interactions médicamenteuses)

An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%. (notice Liothyronine, Interactions médicamenteuses)

Caution should be used when NSAIDs and salicylates are administered concomitantly with lower doses of methotrexate, including XATMEP. (notice Méthotrexate, Interactions médicamenteuses)

The clearance of salicylates may be increased with concurrent use of corticosteroids. (notice Méthylprednisolone, Interactions médicamenteuses)

Salicylates And Other Non-Steroidal Anti-Inflammatory Drugs May decrease the antihypertensive effects of metolazone tablets, USP. (notice Métolazone, Interactions médicamenteuses)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (notice Mésalazine, Interactions médicamenteuses)

…with Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan,… (notice Natéglinide, Interactions médicamenteuses)

In patients given very high doses (3,900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently. (notice Nizatidine, Interactions médicamenteuses)

CHCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, and temazepam. (notice Norelgestromine et éthinylestradiol, Interactions médicamenteuses)

COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. (notice Norgestimate et éthinylestradiol, Interactions médicamenteuses)

COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. (notice Norgestrel et éthinylestradiol, Interactions médicamenteuses)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (notice Mésalazine, Interactions médicamenteuses)

Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (notice Phénylacétate de sodium et benzoate de sodium, Mises en garde et précautions)

…sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antacids Antacids may affect absorption of phenytoin. (notice Phénytoïne, Interactions médicamenteuses)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (notice Pioglitazone et glimépiride, Interactions médicamenteuses)

NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (notice Prednisolone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (notice Mésalazine, Interactions médicamenteuses)

Conversely, agents such as indomethacin, probenecid and salicylates may displace sulfonamides from plasma albumin and increase the concentrations of free drug in plasma. (notice Sulfadiazine, Interactions médicamenteuses)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (notice Mésalazine, Interactions médicamenteuses)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (notice Mésalazine, Interactions médicamenteuses)

Nonsteroidal Anti-Inflammatory Drugs Because torsemide and salicylates compete for secretion by renal tubules, patients receiving high doses of salicylates may experience salicylate toxicity when torsemide is concomitantly administered. (notice Torasémide, Interactions médicamenteuses)

The clearance of salicylates may be increased with concurrent use of corticosteroids. (notice Triamcinolone, Interactions médicamenteuses)

Coadministration of aspirin 150 mg/day with multiple daily doses of TRINTELLIX had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin and salicylic acid [see Clinical Pharmacology (12.3) ] . (notice Vortioxétine, Interactions médicamenteuses)

These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone. (notice Énoxaparine, Interactions médicamenteuses)

In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenylbutazone, and diazepam. (notice Entacapone, Précautions)

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (notice Répaglinide, Interactions médicamenteuses)

Although the exact frequency of occurrence has not been determined, it has occurred in 3% of patients in controlled clinical trials of mesalamine or sulfasalazine. (notice Mésalazine, Mises en garde et précautions)